This is a tax-motivated sale of a small equity vesting tranche, not a change in the CEO's outlook. The filing is routine and does not alter the insider selling pattern. Monitor the next Form 4 for actual execution and any larger open-market sales.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $140.30entry
- T+1 · 13d ago +1.63%α −0.03% · $142.58
- T+5 · 7d ago −5.82%α −5.24% · $132.13
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
CEO Emily M. Leproust filed a Form 144 to sell 4,573 shares of Twist Bioscience common stock, valued at approximately $619,192. The shares were acquired via restricted stock vesting on November 2, 2026, and the sale is intended to cover a tax obligation from the settlement of a vested equity award. This is a routine, small disposition relative to her prior large sales and the company's $11.5B market cap.
Key Facts
- CEO Emily M. Leproust filed Form 144 to sell 4,573 shares of common stock.
- Estimated proceeds of ~$619,192 based on a price of ~$135.40 per share.
- Shares were acquired on November 2, 2026 via restricted stock vesting.
- Sale is to cover a tax obligation from the settlement of a vested equity award.
- Leproust has sold over 600,000 shares in the prior three months (Aug-Oct 2026) for aggregate proceeds exceeding $90M.
- The 4,573 shares represent less than 1% of her recent trading volume and a negligible fraction of the company's 11.5B market cap.
Financial Impact
~$619,192 in proceeds from 4,573 shares sold for tax withholding purposes.
Risk Factors
- CEO has been a consistent large seller over the past three months, which could weigh on sentiment if the pattern continues.
- Form 144 is an intent to sell; the actual sale may not occur or may be at a different price.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-007692 |
| Document: 0001959173-26-007692-index.html | 0001959173-26-007692 |
| Document: 0001959173-26-007692.txt | 0001959173-26-007692 |
Track record
47 reports on TWST
8 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +55.24% at T+60 after the Aug 3, 2026 report. 10 of 12 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $105.03 Now $105.04 +0.01% settles Dec 15
- Nov 16, 2026today 144 Neutral 2/10 Entry $105.16 Now $105.04 −0.11% settles Dec 15
- Nov 16, 2026today 144 Neutral 2/10 Entry $104.98 Now $105.04 +0.06% settles Dec 15
- Nov 16, 2026today 144 Neutral 2/10 Entry $105.61 Now $105.04 −0.54% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $104.03 Now $105.04 +0.98% settles Dec 15
- Nov 12, 20264d ago 8-K Bullish 6/10 Entry $114.22 Now $105.04 −8.04% settles Dec 11
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $114.22 Now $105.04 −8.04% settles Dec 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $132.13 Now $105.04 −20.50% settles Dec 9
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $120.79 Now $105.04 −13.04% settles Dec 7
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $120.61 Now $105.04 −12.91% settles Dec 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers